Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark To Debut Ryaltris In Australia

Rhinitis Therapy Gets TGA Nod For Launch In 2020

Executive Summary

Glenmark ended 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.

You may also be interested in...



Glenmark Celebrates European Ryaltris Approvals

Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.

Glenmark Finds Canadian Ryaltris Partner

Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.

Glenmark Partners With Menarini On Ryaltris

Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149484

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel